Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are a key achievement in the field of migraine prevention, being the first migraine-specific preventatives.1 Several characteristics distinguish monoclonal antibodies targeting the CGRP pathway from the previously available drug classes for migraine prevention, including their specificity, their monthly or quarterly subcutaneous administration, and their rapid onset of action.
The paradigm shift of long-term treatments in migraine prevention
Ornello, Raffaele;Sacco, Simona
2021-01-01
Abstract
Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are a key achievement in the field of migraine prevention, being the first migraine-specific preventatives.1 Several characteristics distinguish monoclonal antibodies targeting the CGRP pathway from the previously available drug classes for migraine prevention, including their specificity, their monthly or quarterly subcutaneous administration, and their rapid onset of action.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
